Search results

3 December 2025 12:00 to 13:00 | Seminar MALMÖ CANCER SEMINARSWednesday December 3rd at 12.00-13.00 at Room 2005/2007, 2nd floor, Målpunkt D, Inga Marie Nilssons gata 47, SUS Malmö or join Zoom: https://lu-se.zoom.us/j/62112735926 Title: “Pharmacological Strategies in Cancer Research: From Target Identification to Therapeutic Response” Speaker: José MoreiraProfessor, Dept. of Drug Design and Pharm

https://www.lucc.lu.se/internal/calendar/lucc-malmo-cancer-seminars-2 - 2025-11-21

- Implementation: Efficiently translating research findings into patient and societal benefit A crucial aim for LUCC is to enable a more efficient implementation of research findings into clinical practice and in generating innovations for sustainable growth. Importantly, LUCC provides support to facilitate the transition of basic research findings into clinical trials and clinical practice, as we

https://www.lucc.lu.se/internal/innovation-collaboration - 2025-11-21

LUCC supports and promotes innovation LUCC work on the commercialization of cancer research in collaboration with LU Innovation. We identify and evaluate commercially viable projects together with researchers, as well as facilitate and support the process from idea to company formation or licensing.Innovation support needed?LUCC Innovation Manager Cecilia Jädert can help you to develop your resear

https://www.lucc.lu.se/internal/innovation-collaboration/innovation - 2025-11-21

We provide you with free commercial advice throughout the process. Our experienced business developers have worked in both academia and industry. Our primary task is to guide and move you forward but all projects are different and there are no ready-made solutions. And remember – without your commitment there is no project to work with. We usually start by mapping the situation, looking at aspects

https://www.lucc.lu.se/internal/innovation-collaboration/innovation/idea-and-business-development-lu-innovation - 2025-11-21

Internal Reference Group (heads of strategic networks)Sara Alkner (Breast)Daniel Ansari (Gastrointestinal)Håkan Axelson (UroCan-LUCC)Monika Bauden (Gastrointestinal)Daniel Bexell (Child)Pamela Buchwald (Gastrointestinal)Ana Carneiro (Clinical trials & drug development)Ida Dalene Skarping (Imaging & nuclear medicine/radiology)Maria Gebre-Medhin (Head & neck)Lennart Greiff (Head & neck)Anna Hagström

https://www.lucc.lu.se/internal/organisation-governance/internal-reference-group - 2025-11-21

Calendar Link to RSS 25 November 2025 13:00 to 26 November 2025 15:00 | Conference LUCC - Gynaecology: National SweOCRN Conference 26 November 2025 12:00 to 15:45 | Seminar LUCC - Cancer epidemiology: Half day seminar 27 November 2025 10:00 to 11:00 | Seminar LUCC - Hematology: Special Seminar 27 November 2025 13:00 to 16:00 | Meeting LUCC: Clinical Trials & Diagnostics - Kick-off meeting 28 Novem

https://www.lucc.lu.se/internal/home - 2025-11-21

The website is managed by Lund University Cancer Center administration. We want as many people as possible to be able to use the site. This document describes how www.lucc.lu.se/internal complies with the accessibility regulations, any known accessibility issues, and how you can report problems so we can fix them How accesssible is www.lucc.lu.se/internal?We know some parts of this website aren't

https://www.lucc.lu.se/internal/accessibility-wwwluccluseinternal - 2025-11-21

We are a platform that unites pre-clinical and clinical researchers at Lund University, focused tumor microenvironment profiling, immunotherapy discovery and development, and the application of immunotherapies in the clinic. Our Mission:Showcase current research in tumor microenvironment and immunotherapy at LU.Promote interaction and collaboration among research groups in the network.Drive excell

https://www.lucc.lu.se/internal/research/strategic-networks/immunotherapy-and-tumor-microenvironment-network - 2025-11-21

https://www.lucc.lu.se/internal/landing-page - 2025-11-21

In June 2022, Sofia Bergh started her PhD studies in TNU supervised by Prof. Åsa Petersén. The overall aim of the PhD project is to investigate the cellular and molecular mechanisms of limbic system pathology of Huntington’s disease. Her first original research article is in press titled “Effects of mutant huntingtin in oxytocin neurons on non-motor features of Huntington’s disease” in Neuropathol

https://www.huntington-research.lu.se/team/sofia-bergh-phd-student - 2025-11-21

Weydt P, Dupuis L and Petersen Å. Handbook of Clinical Neurology 157: 761-775 (2018) Abstract Huntington disease (HD) is a paradigmatic autosomal-dominant adult-onset neurodegenerative disease. Since the identification of an abnormal expansion of a trinucleotide repeat tract in the huntingtin gene as the underlying genetic defect, a broad range of transgenic animal models of the disease has become

https://www.huntington-research.lu.se/thermoregulatory-disorders-huntington-disease - 2025-11-21

Baldo B, Soylu R and Petersén ÅPLoS One 8(12) (2013)AbstractHuntington's disease (HD) is a fatal neurodegenerative disorder caused by an expanded polyglutamine repeat in the huntingtin protein. Neuropathology in the basal ganglia and in the cerebral cortex has been linked to the motor and cognitive symptoms whereas recent work has suggested that the hypothalamus might be involved in the metabolic

https://www.huntington-research.lu.se/maintenance-basal-levels-autophagy-huntingtons-disease-mouse-models-displaying-metabolic-dysfunction - 2025-11-21

Bergh S, Gabery S, Tonetto S, Kirik D, Petersén Å and Cheong RY. Neuropathology and Applied Neurobiology. 2023;49(2):e12891. doi:10.1111/nan.12891 [published correction appears in Neuropathol Appl Neurobiol. 2023 Jun;49(3):e12905]. Abstract Background: Early non-motor features including anxiety, depression and altered social cognition are present in Huntington's disease (HD). The underlying neurob

https://www.huntington-research.lu.se/effects-mutant-huntingtin-oxytocin-neurons-non-motor-features-huntingtons-disease - 2025-11-21

In May 2022, Karin Dalene Skarping started her PhD studies in TNU supervised by Prof. Åsa Petersén. The overall aim of the PhD project is to study genetic mechanisms that may modify the disease course and pathology of Huntington disease. One of her current research projects is aimed to examine associations between germline pathogenic variants in mismatch-repair (MMR) genes and CAG-repeats in HTT,

https://www.huntington-research.lu.se/team/karin-dalene-skarping-phd-student - 2025-11-21

Sofia Hult Lundh1, Nathalie Nilsson1, Rana Soylu1, Deniz Kirik2 and Åsa Petersén1.1Translational Neuroendocrine Research Unit, Department of Experimental Medical Science, Lund University, Lund SE-221 84, Sweden.2Brain Repair and Imaging in Neural Systems (BRAINS) Unit, Department of Experimental Medical Science, Lund University, Lund SE-221 84, Sweden.Human Molecular Genetics 22: 3485-3497 (2013)A

https://www.huntington-research.lu.se/hypothalamic-expression-mutant-huntingtin-contributes-development-depressive-behavior-bac-transgenic - 2025-11-21

Linda Holmquist Mengelbier is a paediatric cancer researcher who now, in parallel to her cancer effort, has started to work with the neurodegenerative disorders Huntington disease and ALS. Her focus in the cancer field has been on the embryonal pediatric solid tumors neuroblastoma and Wilms tumor. Neuroblastoma is a sympathetic nervous system tumor derived from the neural crest, whereas Wilms tumo

https://www.huntington-research.lu.se/team/linda-holmquist-mengelbier-phd - 2025-11-21

Soylu-Kucharz R, Adlesic N, Davidsson M, Björklund T, Björkqvist M and Petersén Å. bioRxiv 2023.03.04.530949; First published March 4, 2023, https://doi.org/10.1101/2023.03.04.530949 Abstract Huntington’s disease is a fatal neurodegenerative disorder caused by an expanded CAG triplet repeat in the huntingtin (HTT) gene. Previous research focused on neuropathology in the striatum and its associatio

https://www.huntington-research.lu.se/mutant-huntingtin-expression-hypothalamus-promotes-ventral-striatal-neuropathology - 2025-11-21

Dalene Skarping K, Arning L, Petersén Å, Nguyen HP and Gebre-Medhin S.Sci Rep. 2024;14(1):4300. Published 2024 Feb 21. doi:10.1038/s41598-024-54277-5AbstractDNA mismatch repair (MMR) is thought to contribute to the onset and progression of Huntington disease (HD) by promoting somatic expansion of the pathogenic CAG nucleotide repeat in the huntingtin gene (HTT). Here we have studied constitutional

https://www.huntington-research.lu.se/attenuated-huntingtin-gene-cag-nucleotide-repeat-size-individuals-lynch-syndrome - 2025-11-21

Lilja Andersson P, Juth N, Petersén Å, Graff C and Edberg AE.Lund University, Sweden.Nursing Ethics 20: 189-199 (2013)AbstractThe aim of this study was to describe the experiences of undergoing a presymptomatic genetic test for the hereditary and fatal Huntington’s disease, using a case study approach. The study was based on 18 interviews with a young woman and her husband from the decision to und

https://www.huntington-research.lu.se/ethical-aspects-undergoing-predictive-genetic-testing-huntingtons-disease - 2025-11-21

In 2024, Jennifer moved from Sydney, Australia to Lund, Sweden to start her PhD studies at the TNU, supervised by Pof. Åsa Petersén. In utilizing novel AAV-vectors and crossbreeding of animal models, Jennifer’s project aims to elucidate the specific hypothalamic circuitries important for the control of metabolism and emotion, with relevance to Huntington’s Disease, Amyotrophic Lateral Sclerosis an

https://www.huntington-research.lu.se/team/jennifer-oraha-phd-student - 2025-11-21